Drug Trial Radar · NCT07262619
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Jan 20, 2026
Primary completion
Mar 2029
Study completion Mar 2029
Sponsor
- Lead sponsor
- Eikon TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Dec 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.
Conditions
- Advanced Solid Tumors
- MSI-H or dMMR Advanced Solid Tumors
- MSI-H/dMMR Gastric Cancer
- MSI-H/dMMR Colorectal Cancer
- MSI-H/dMMR Gastroesophageal-junction Cancer
- Endometrial Cancer
- Mismatch Repair Deficient or MSI-High Solid Tumors
Interventions
EIK1005Drug
EIK1005 is a selective inhibitor of the Werner helicase.
pembrolizumab (KEYTRUDA® )Drug
Pembrolizumab is a PD-1 inhibitor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-Limiting Toxicity (DLT) - Part 1Time frame: 21 Days
- Adverse Events (AEs) - Part 1 and Part 2Time frame: From the time of first dose of study medication through 30 days following cessation of study treatment.
Locations
45 sites in 15 countries. Site status is shown where the registry gives one.
California Research Institute (CRI)
Los Angeles, California · Recruiting
Omnicure Clinical Research
Doral, Florida · Recruiting
Bioresearch Partner
Hialeah, Florida · Recruiting
Florida Clinical Trials Group
Plantation, Florida · Recruiting
Florida Clinical Trials Group - Tamarac
Tamarac, Florida · Recruiting
Morristown Medical Center
Morristown, New Jersey · Recruiting
START New York-Long Island
Lake Success, New York · Recruiting
Memorial Sloan Kettering Cancer Center (MSKCC)
New York, New York · Recruiting
START Dallas Fort Worth
Fort Worth, Texas · Recruiting
University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
GenesisCare North Shore (Oncology)
Saint Leonards, New South Wales, Australia · Not yet recruiting
Calvary Mater Newcastle Hospital
Waratah, New South Wales, Australia · Recruiting
Grampians Health
Ballarat, Victoria, Australia · Recruiting
Chris O'Brien Lifehouse (Sydney Cancer Centre)
Camperdown, Victoria, Australia · Recruiting
Oncology Clinics Victoria (OCV) - Cabrini Brighton Hospital
Frankston, Victoria, Australia · Recruiting
Peninsula and Southeast Oncology (PASO) Medical
Frankston, Victoria, Australia · Recruiting
Ordensklinikum Linz Elisabethinen
Linz, Austria · Recruiting
Centre Hospitalier Universitaire Brugmann - Victor Horta
Brussels, Belgium · Recruiting
Kuopio University Hospital
Kuopio, Finland · Recruiting
Hospices Civils De Lyon (hcl) -Centre Hospitalier Lyon-Sud
Pierre-Bénite, Rhone, France · Recruiting
Helios Klinikum Berlin-Buch
Berlin, Germany · Recruiting
Norddeutsches Studienzentrum fur Innovative Onkologie (NIO) Hamatologisch Onkologische Praxis Eppendorf (HOPE)
Hamburg, Germany · Recruiting
DONAUISAR Klinikum
Deggendorf, Bavaria, Germany · Recruiting
Campus Bio-Medico di Rome University
Rome, Italy · Recruiting
Health New Zealand
Wellington, New Zealand · Recruiting
Palmerstone North Hospital
Roslyn, Manawatu, New Zealand · Recruiting
Oslo University
Oslo, Norway · Recruiting
GCPMED Sp. z o.o., Centrum Medyczne iMed24
Krakow, Poland · Recruiting
Centrum Terapii Wspolczesnej J.M. Jasnorzewska Spolka Komandytowo-Akcyjna
Lodz, Poland · Recruiting
One Day Med
Szczecin, West Pomeranian Voivodeship, Poland · Recruiting
Hospital de Santa Maria
Lisbon, Portugal · Recruiting
Unidade Local de Saúde (ULS) Loures Odivelas
Loures, Portugal · Recruiting
Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E. (IPO Porto)
Porto, Portugal · Recruiting
Hospital da Luz Lisboa
Lisbon, Lisbon District, Portugal · Recruiting
National University Hospital (NUH)
Singapore, Singapore · Recruiting
National Cancer Centre Singapore (NCCS)
Singapore, Central Region, Singapore · Recruiting
Korea University Anam Hospital
Seoul, South Korea · Recruiting
Ajou University School of Medicine & Graduate School of Medicine
Suwon, South Korea · Recruiting
Inje University-Haeundae Paik Hospital
Busan, Busan, South Korea · Recruiting
START - Barcelona
Barcelona, Spain · Recruiting
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.